Optimal population screening policies for Alzheimer’s disease*

References

• AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): Randomised double-blind trial. The Lancet, 363(9427), 2105–2115.
   Web of Science ®Google Scholar
• Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 270–279.
   PubMed Web of Science ®Google Scholar
• Alemayehu, B. and Warner, K. E. (2004) The lifetime distribution of health care costs. Health Services Research, 39(3), 627–642.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease Neuroimaging Initiative (2006). ADNI Procedures Manual. Available at: http://adni.loni.usc.edu/wp-content/uploads/2010/09/ADNI_GeneralProceduresManual.pdf.
   Google Scholar
• Andersen, P. K. (1988) Multistate models in survival analysis: A study of nephropathy and mortality in diabetes. Statistics in Medicine, 7(6), 661–670.
   Web of Science ®Google Scholar
• Alzheimer's Association. (2017) 2017 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 13(4), 325–373.
   Google Scholar
• Ayer, T., Alagöz, O., and Stout, N. K. (2012) OR forum: A POMDP approach to personalize mammography screening decisions. Operations Research, 60(5), 1019–1034.
   Web of Science ®Google Scholar
• Barnett, J. H., Lewis, L., Blackwell, A. D., and Taylor, M. (2014) Early intervention in Alzheimer’s disease: A health economic study of the effects of diagnostic timing. BMC Neurology, 14(1), 101.
   PubMedGoogle Scholar
• Bond, J., Graham, N., Padovani, A., Mackell, J., Knox, S., and Atkinson, J. (2010) Screening for cognitive impairment, Alzheimer’s disease and other dementias: Opinions of European caregivers, payors, physicians and the general public. The Journal of Nutrition, Health & Aging, 14(7), 558–562.
   Web of Science ®Google Scholar
• Brazier, J. (2007) Measuring and Valuing Health Benefits for Economic Evaluation. Oxford University Press, Oxford.
   Google Scholar
• Cohen, J. T. and Neumann, P. J. (2008) Decision analytic models for Alzheimer’s disease: State of the art and future directions. Alzheimer’s & Dementia, 4(3), 212–222.
   Web of Science ®Google Scholar
• Cullen, B., O’Neill, B., Evans, J. J., Coen, R. F., and Lawlor, B. A. (2007) A review of screening tests for cognitive impairment. Journal of Neurology, Neurosurgery & Psychiatry, 78(8), 790–799.
   PubMed Web of Science ®Google Scholar
• Dixon, J., Ferdinand, M., D’Amico, F., and Knapp, M. (2014) Exploring the cost-effectiveness of a one-off screen for dementia (for people aged 75 years in England and Wales). International Journal for Geriatric Psychiatry, 30(5), 446–452.
   Web of Science ®Google Scholar
• Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. The Lancet Neurology, 6(8), 734–746.
   PubMed Web of Science ®Google Scholar
• Duthey, B. (2013) Background paper 6.11: Alzheimer disease and other dementias. A Public Health Approach to Innovation, 1–74.
   Google Scholar
• Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975) Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.
   PubMed Web of Science ®Google Scholar
• Getsios, D., Blume, S., Ishak, K. J., Maclaine, G., and Hernández, L. (2012) An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimer’s & Dementia, 8(1), 22–30.
   Web of Science ®Google Scholar
• Gillies, C. L., Lambert, P. C., Abrams, K. R., Sutton, A. J., Cooper, N. J., Hsu, R. T., Davies, M. J., Khunti, K., et al. (2008) Different strategies for screening and prevention of type 2 diabetes in adults: Cost effectiveness analysis. British Medical Journal, 336(7654), 1180–1185.
   PubMed Web of Science ®Google Scholar
• Green, C. (2007) Modelling disease progression in Alzheimer’s disease. Pharmacoeconomics, 25(9), 735–750.
   PubMed Web of Science ®Google Scholar
• Green, C., Shearer, J., Ritchie, C. W., and Zajicek, J. P. (2011) Model-based economic evaluation in Alzheimer’s disease: A review of the methods available to model Alzheimer’s disease progression. Value Health, 14(5), 621–630.
   Web of Science ®Google Scholar
• Hampel, H., Bürger, K., Teipel, S. J., Bokde, A. L., Zetterberg, H., and Blennow, K. (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimer’s & Dementia, 4(1), 38–48.
   PubMed Web of Science ®Google Scholar
• Harper, P. and Jones, S. (2005) Mathematical models for the early detection and treatment of colorectal cancer. Health Care Management Science, 8(2), 101–109.
   Google Scholar
• Henriksen, K., O’Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss-Coray, T., Soares, H., et al. (2014) The future of blood-based biomarkers for Alzheimer’s disease. Alzheimer’s & Dementia, 10(1), 115–131.
   PubMed Web of Science ®Google Scholar
• Jackson, C. (2011) Multi-state models for panel data: The MSM package for r. Journal of Statistical Software, 38(1), 1–28.
   Google Scholar
• Jackson, C. H., Sharples, L. D., Thompson, S. G., Duffy, S. W., and Couto, E. (2003) Multistate Markov models for disease progression with classification error. Journal of the Royal Statistical Society: Series D (The Statistician), 52(2), 193–209.
   Google Scholar
• Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., and van den Bussche, H. (2005) Cholinesterase inhibitors for patients with Alzheimer’s disease: Systematic review of randomised clinical trials. British Medical Journal, 331(7512), 321–327.
   PubMedGoogle Scholar
• Khachaturian, Z. S., Barnes, D., Einstein, R., Johnson, S., Lee, V., Roses, A., Sager, M. A., Shankle, W. R., Snyder, P. J., Petersen, R. C., et al. (2010) Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimer’s & Dementia, 6(2), 89–97.
   Web of Science ®Google Scholar
• Khachaturian, Z. S., Khachaturian, A. S., and Thies, W. (2012) The draft national plan to address Alzheimer’s disease: National Alzheimer’s Project Act (NAPA). Alzheimer’s & Dementia, 8(3), 234–236.
   Web of Science ®Google Scholar
• Khachaturian, Z. S., Petersen, R. C., Snyder, P. J., Khachaturian, A. S., Aisen, P., De Leon, M., Greenberg, B. D., Kukull, W., Maruff, P., Sperling, R. A., et al. (2011) Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010. Alzheimer’s & Dementia, 7(2), 127–132.
   Web of Science ®Google Scholar
• Kirby, J., Green, M. C., Loveman, E., Clegg, A., Picot, J., Takeda, A., and Payne, E. (2006) A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer’s disease. Drugs & Aging, 23(3), 227–240.
   Web of Science ®Google Scholar
• K irk izlar, E., Faissol, D. M., Griffin, P. M., and Swann, J. L. (2010) Timing of testing and treatment for asymptomatic diseases. Mathematical Biosciences, 226(1), 28–37.
   Web of Science ®Google Scholar
• Kmietowicz, Z. (2012) Cameron launches challenge to end “national crisis” of poor dementia care. British Medical Journal, 344, e2347.
   Google Scholar
• Koepsell, T. D. and Monsell, S. E. (2012) Reversion from mild cognitive impairment to normal or near-normal cognition risk factors and prognosis. Neurology, 79(15), 1591–1598.
   PubMed Web of Science ®Google Scholar
• Kurt, M., Denton, B. T., Schaefer, A. J., Shah, N. D., and Smith, S. A. (2011) The structure of optimal statin initiation policies for patients with type 2 diabetes. IIE Transactions on Healthcare Systems Engineering, 1(1), 49–65.
   Google Scholar
• Leon, J., Cheng, C.-K., and Neumann, P. J. (1998) Alzheimer’s disease care: costs and potential savings. Health Affairs, 17(6), 206–216.
   PubMed Web of Science ®Google Scholar
• Leon, J. and Neumann, P. J. (1999) The cost of Alzheimer’s disease in managed care: A cross-sectional study. American Journal of Managed Care, 5(7), 867–877.
   Web of Science ®Google Scholar
• López-Bastida, J., Hart, W., García-Pérez, L., and Linertová, R. (2009) Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Journal of Alzheimer’s Disease, 16(2), 399–407.
   Web of Science ®Google Scholar
• MacDonald, I. L. and Zucchini, W. (1997) Hidden Markov and other Models for Discrete-valued Time Series, volume 110. CRC Press, Boca Raton, FL.
   Google Scholar
• Maillart, L. M., Ivy, J. S., Ransom, S., and Diehl, K. (2008) Assessing dynamic breast cancer screening policies. Operations Research, 56(6), 1411–1427.
   Web of Science ®Google Scholar
• Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., and Kivipelto, M. (2010) Alzheimer’s disease: Clinical trials and drug development. The Lancet Neurology, 9(7), 702–716.
   PubMed Web of Science ®Google Scholar
• McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984) Clinical diagnosis of Alzheimer’s disease report of the NINDCS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34(7), 939–939.
   PubMed Web of Science ®Google Scholar
• Morris, J. C. (1993) The clinical dementia rating (CDR): Current version and scoring rules. Neurology, 43(11), 2412–2414.
   PubMed Web of Science ®Google Scholar
• Morris, J. C. (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. International Psychogeriatrics, 9(S1), 173–176.
   PubMedGoogle Scholar
• National Institute for Clinical Excellence (NICE) et al. (2011) Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. NICE Technology Appraisal Guidance, 217, 1-76.
   Google Scholar
• Neumann, P., Araki, S., Arcelus, A., Longo, A., Papadopoulos, G., Kosik, K. A., Kuntz, K., and Bhattacharjya, A. (2001) Measuring Alzheimer’s disease progression with transition probabilities estimates from CERAD. British Medical Journal, 57(6), 957–964.
   Google Scholar
• Neumann, P. J., Kuntz, K. M., Leon, J., Araki, S. S., Hermann, R. C., Hsu, M.-A., and Weinstein, M. C. (1999) Health utilities in Alzheimer’s disease: A cross-sectional study of patients and caregivers. Medical Care, 37(1), 27–32.
   Web of Science ®Google Scholar
• Özekici, S. and Pliska, S. R. (1991) Optimal scheduling of inspections: A delayed Markov model with false positives and negatives. Operations Research, 39(2), 261–273.
   Web of Science ®Google Scholar
• Parmigiani, G. (1993) On optimal screening ages. Journal of the American Statistical Association, 88(422), 622–628.
   Web of Science ®Google Scholar
• Perneczky, R., Wagenpfeil, S., Komossa, K., Grimmer, T., Diehl, J., and Kurz, A. (2006) Mapping scores onto stages: Mini-mental state examination and clinical dementia rating. American Journal of Geriatric Psychiatry, 14(2), 139-144.
   Web of Science ®Google Scholar
• Prince, M. J. (2015) World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer’s Disease International, London, England.
   Google Scholar
• Puterman, M. L. (1994) Markov Decision Processes: Discrete Stochastic Dynamic Programming. John Wiley & Sons, Hoboken, New Jersey.
   Google Scholar
• Satten, G. A. and Longini Jr., I. M. (1996) Markov chains with measurement error: Estimating the true course of a marker of the progression of human immunodeficiency virus disease. Applied Statistics, 45(3), 275–309.
   Web of Science ®Google Scholar
• Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280–292.
   PubMed Web of Science ®Google Scholar
• Touchon, J., Lachaine, J., Beauchemin, C., Granghaud, A., Rive, B., and Bineau, S. (2014) The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: Cost-effectiveness analysis in France. European Journal of Health Economics, 15(8), 791–800.
   PubMed Web of Science ®Google Scholar
• UK National Screening Committee (2015). Screening in the UK: Making Effective Recommendations 2014 to 2015. Public Health England, London.
   Google Scholar
• Underwood, D., Zhang, J., Denton, B., Shah, N., and Inman, B. (2012) Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Management Science, 15(4), 293–309.
   Web of Science ®Google Scholar
• Weimer, D. L. and Sager, M. A. (2009) Early identification and treatment of Alzheimer’s disease: Social and fiscal outcomes. Alzheimer’s & Dementia, 5(3), 215–226.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2012) Dementia: A Public Health Priority. World Health Organization, Geneva.
   Google Scholar
• Youden, W. J. (1950) Index for rating diagnostic tests. Cancer, 3(1), 32–35.
   PubMed Web of Science ®Google Scholar
• Yu, S.-Y., Lee, T.-J., Jang, S.-H., Han, J. W., Kim, T. H., and Kim, K. W. (2015) Cost-effectiveness of nationwide opportunistic screening program for dementia in South Korea. Journal of Alzheimer’s Disease, 44(1), 195–204.
   Web of Science ®Google Scholar
• Zhang, J., Denton, B. T., Balasubramanian, H., Shah, N. D., and Inman, B. A. (2012) Optimization of prostate biopsy referral decisions. Manufacturing & Service Operations Management, 14(4), 529–547.
   Google Scholar